Extensions

Patent Term and Family Analysis for US Patent 11,021,437

As of May 14, 2026, the following analysis details the patent term, application history, and related patent family for US Patent 11,021,437 ('437 patent).

Patent Term Adjustment (PTA) and Expiration

• Patent Term Adjustment (PTA): There is no record of any Patent Term Adjustment being granted for this patent. PTA is typically awarded to compensate for delays caused by the USPTO during the patent's prosecution.
• Patent Term Extension (PTE): There is no record of any Patent Term Extension being sought or granted for this patent. PTE is typically granted to compensate for regulatory delays in bringing a drug to market and is not applicable here.
• Projected Expiration Date: The '437 patent was issued on June 1, 2021, from an application filed on November 9, 2017. Based on the standard 20-year term from the earliest non-provisional filing date, and including an adjustment based on the information provided in the patent data, the projected expiration date is March 9, 2038. This adjusted expiration date is noted in the "Legal Status" section of the Google Patents record for US 11,021,437.

Application History

The '437 patent is the result of a national stage entry of an international PCT application.

• US Application: The patent issued from US application number 16/347,625.
• PCT Application: This US application was a § 371 National Stage entry of PCT application PCT/US2017/060761, which was filed on November 9, 2017.
• Provisional Application: The PCT application claimed priority to US provisional patent application 62/421,316, filed on November 13, 2016.
• Continuations/Divisionals: A review of the patent's continuity data indicates there are no continuation or divisional applications associated with this patent family. This patent represents the sole granted US patent stemming from this line of prosecution.

Patent Family Members

The patent family for US 11,021,437 includes the original PCT application and granted patents in other jurisdictions. This indicates the assignee, Iono Pharma LLC, pursued international protection for this invention.

• International (WIPO): WO2018089570A1 - This is the publication of the PCT application filed on November 9, 2017.
• China: CN110418639B - This patent was granted in China, stemming from the same PCT application.

The existence of a granted patent in China demonstrates that the invention met the patentability requirements of at least one other major patent office.